The supervisory board of private joint-stock company Biofarma (Kyiv) on October 21, 2015 decided to close a company representative office in Belarus due to the restructuring of the company.
The company said that Biofarma fulfilled presentation functions in Belarus and was not involved in commercial operations.
As reported, on October 15, 2015, the supervisory board of Biofarma decided to close its representative office in Kazakhstan.
Biofarma is among the ten largest Ukrainian drug manufactures. Biofarma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.
Advertising
Advertising
MORE ABOUT
STADA to Become a Major Pharma Player in Ukraine by Acquiring Biopharma’s Pharmaceutical Prescription and Consumer Health Business
10:01, 02.12.2019
Govt permits Biofarma Plasma to export blood preparations in 2018
17:13, 02.01.2018
Biofarma could open blood plasma fractionator plant in July 2018
11:50, 15.12.2017
Biofarma Plazma receives heat production license
16:38, 21.11.2017
Biofarma to seek review of UNDP decision on outcome of tender for blood purchases
17:51, 19.05.2017
LATEST
Southern cluster of TAS Agro will sow sunflower on 2,764 ha in 2025 season
20:37, 03.04.2025
EBRD, IFC and Black Sea Trade and Development Bank provide Galnaftogaz with EUR157 mln loan for 147 MW wind farm in Volyn
17:29, 03.04.2025
Ukraine will be able to ensure predictability of trade flows to EU – Kachka
15:39, 03.04.2025
U.S. 10% tariff to hit small manufacturers the hardest, but efforts underway to improve conditions – Ukraine's Deputy PM
12:16, 03.04.2025
Trump announces introduction of reciprocal tariffs on imports, Ukraine receives 10%